A randomized, placebo‐controlled, double‐blind study of hysteroscopic‐guided pertubal diluted bupivacaine infusion for endometriosis‐associated chronic pelvic pain

Abstract Objective To assess the effectiveness of hysteroscopic-guided pertubal diluted bupivacaine infusion for endometriosis-associated chronic pelvic pain (CPP). Methods Between June 2010 and July 2013, a randomized, placebo-controlled, double-blind study was undertaken at Mansoura University Hospital, Mansoura, Egypt. Patients meeting inclusion criteria (laparoscopically confirmed endometriosis, patent fallopian tubes, ≥ 6 months CPP, pain score on visual analogue scale [VAS] > 5) were randomly assigned using a computer-generated randomization sequence to receive either office hysteroscopic-guided pertubal diluted bupivacaine infusion (0.25%) or placebo. Response to treatment was assessed using subjective data for scores on VAS and a monthly verbal rating scale (VRS monthly ) at baseline and at 1, 2, and 3 months of follow-up. Additionally, women completed a questionnaire to evaluate the overall satisfaction at 3 months. Results Thirty patients were assigned to each group. In the bupivacaine group, VAS and VRS monthly scores were significantly lower at 1, 2, and 3 months than at baseline ( P P P  = 0.18). Conclusion Office pertubal hysteroscopic-guided diluted bupivacaine infusion could be used to manage endometriosis-associated CPP for at least 3 months. AEARCTR-0000573